Comparison of pegylated interferon α‐2b plus psoralen PUVA versus standard interferon α‐2a plus PUVA in patients with cutaneous T‐cell lymphoma

Abstract

In patients with cutaneous T-cell lymphoma PEG-IFN α-2b plus PUVA might become a promising treatment alternative as its higher rate of myelosuppression and liver toxicity is outweighed by its lower percentage of constitutional side-effects, and its significantly higher overall response. Due to the small number of participants at this retrospective study, a larger prospective study is essential to verify our results.